Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deals Of The Week: BioCryst/Presidio, Merck/AiCuris, Kite/National Cancer Institute

Executive Summary

The termination of a Phase III trial for Abbott/Reata’s projected blockbuster bardoxolone is just one of several recent major blow-ups of a significant pharma/biotech collaboration. One analyst thinks narrow, short-term thinking by business development execs links all of the clinical letdowns.

Advertisement

Related Content

Bardoxolone Blow-Up: Reata/Abbott CKD Drug Halted In Phase III
Merck’s CV Pipeline: A Shrinking But Strident Commitment
Chimerix Chooses Merck As HIV Partner, Keeps Broad-Spectrum Antiviral
MedImmune Pipeline Primed To Produce
Merck Drops Development Of Cardiome’s Oral Vernakalant
Targacept, AstraZeneca Face Another Failure With NNR Class
Pfizer/Medivation End Dimebon Development Following Another Failed Alzheimer’s Trial
AstraZeneca Opts Out Of Targacept Schizophrenia Program
AstraZeneca Drops Targacept's Failed ADHD Drug
Amdipharm: From Pharmacist to Pharma Firm

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS054824

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel